MGTX Gene Therapy Hits 3-Year Durability Milestone for Xerostomia

MeiraGTx Holdings plc (MGTX) reported three-year follow-up data from its Phase I clinical trial for AAV-hAQP1, a gene therapy candidate designed to treat radiation-induced xerostomia. The company is positioning the therapy as a potential long-term solution for patients suffering from chronic dry mouth following head and neck cancer radiation treatment.

Long-Term Durability and Clinical Objectives

The trial data focuses on the sustained expression of the hAQP1 gene, which aims to restore salivary function in patients with damaged glands. By targeting the underlying physiological deficit rather than merely managing symptoms with palliative care, MeiraGTx is attempting to carve out a specialized niche in the gene therapy space. The three-year mark serves as a critical benchmark for durability in gene therapy, providing a clearer picture of whether the viral vector maintains therapeutic protein production over time.

"The long-term safety and efficacy profile observed in our Phase I study provides a strong foundation for the continued clinical advancement of AAV-hAQP1 as we move toward late-stage development," management noted during the briefing.

Commercial Landscape and Market Opportunity

Radiation-induced xerostomia represents a significant burden for head and neck cancer survivors, impacting nutrition, speech, and overall quality of life. Current standards of care are largely limited to saliva substitutes and stimulants, which often offer only temporary relief. MeiraGTx estimates the total addressable market by focusing on the subset of patients with residual glandular function who can benefit from gene-mediated restoration.